Tough Q3 For Roche But Diagnostics Soften The Blow
Biosimilar Competition Keeps Biting
The Swiss major's old guard of oncology products continue to falter but Roche's new wave of treatments is helping to keep the financials fairly healthy.
The Swiss major's old guard of oncology products continue to falter but Roche's new wave of treatments is helping to keep the financials fairly healthy.